phenylacetate carboxymethyl benzylamide dextran

dextran derivative; has a potent inhibitory effect on epidermoid carcinoma growth associated with an intratumour microvascular network diminution and an aponecrosis increase; as this drug is nontoxic at efficient dose, it offers interesting perspectives for the therapy of malignant lesions; structure in first source

Also Known As:

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Crépin, M: 1 article (06/2003)
2.	Di Benedetto, M: 1 article (06/2003)
3.	Kraemer, M: 1 article (06/2003)
4.	Perret, G Y: 1 article (06/2003)
5.	Starzec, A: 1 article (06/2003)
6.	Vassy, R: 1 article (06/2003)

Related Diseases

1.	Squamous Cell Carcinoma (Epidermoid Carcinoma) 06/16/2003 - "We investigated the effect of a new dextran derivative, phenylacetate carboxymethyl benzylamide dextran (NaPaC), on epidermoid carcinoma A431 cells secreting a large quantity of angiogenic factor, vascular endothelial growth factor (VEGF). "

Related Drugs and Biologics

1.	Angiogenesis Inducing Agents (Angiogenesis Factor)
2.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
3.	Dextrans (Dextran)